强化治疗可减轻亚临床滑膜炎、降低疾病活动度并减少临床缓解期类风湿关节炎患者的复发:一项随机对照试验
本研究为1年开放标签随机对照试验,纳入108例DAS28-CRP≤3.2但超声存在亚临床滑膜炎的类风湿关节炎患者,随机分为维持治疗组与强化治疗组各54例。结果显示强化治疗组复发率显著低于维持治疗组(9.1% vs 24.1%,p=0.039),且超声PD和GS评分下降更显著,临床疾病活动度改善仅见于强化治疗组,两组不良事件相当。
要点
- 超声存在亚临床滑膜炎的临床缓解/低活动度RA患者,强化治疗可显著降低1年复发率。
- 强化治疗组超声PD和GS评分下降及临床疾病活动度改善均优于维持治疗组。
- 两组不良事件相当,但强化组肝功能异常例数较多(16/24例)。
核心结论
- 强化治疗可减轻超声亚临床滑膜炎、改善临床疾病活动度并预防已获临床缓解或低活动度RA患者复发,安全性与维持治疗相当。
研究设计与样本
- 1年开放标签随机对照临床试验,纳入108例DAS28-CRP≤3.2但超声存在亚临床滑膜炎的RA患者,按1:1随机分为维持治疗组与强化治疗组各54例。
主要发现
- 1年随访期间维持治疗组复发率显著高于强化治疗组,全部入组患者为24.1%(13/54)vs 9.1%(5/54),p=0.039。
- 在基线处于缓解的患者中,维持治疗组与强化治疗组复发率分别为26.2%(11/42)vs 5.3%(2/38),p=0.026。
- 两组12个月时GS和PD评分均下降,但强化治疗组下降更显著。
- 临床疾病活动度评分的改善仅见于强化治疗组,维持治疗组未见改善。
- 两组不良事件相当,肝功能异常见于24例(22%),其中16例来自强化治疗组。
关键数值与推荐
- 临床缓解/低疾病活动度定义为DAS28-CRP≤3.2。
- 亚临床滑膜炎定义为超声PD≥1和/或GS≥2。
- 复发定义为DAS28-CRP>3.2且较基线增加≥0.6。
- 主要结局为RA复发率,次要结局为每次访视时PD和GS评分及临床疾病活动度较基线的变化。
临床怎么用
- 对临床缓解或低活动度但超声仍存在亚临床滑膜炎的RA患者,可考虑强化治疗以降低复发风险并改善超声及临床结局。
- 强化治疗期间需关注肝功能异常,本研究中肝功能异常24例中16例来自强化治疗组。
局限性
- 本研究为开放标签设计,未设盲。
- 原文未报告其他局限性信息。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Whether intensive therapy can alleviate subclinical synovitis and reduce flare in rheumatoid arthritis (RA) patients in clinical remission remains unclear. We designed a 1-year open-labelled, randomized controlled clinical trial to elucidate this question. METHODS: RA patients in clinical remission/low disease activity (defined by DAS28-CRP≤ 3.2), however with subclinical synovitis on ultrasound [power Doppler (PD)≥1 and/or gray scale (GS)≥2] were randomized to receive maintenance or intensive treatment at a ratio of 1:1. The primary outcome was the rate of RA relapse (defined by DAS28-CRP>3.2 and an increase≥0.6). The secondary outcomes were changes of PD and GS scores, and clinical disease activity at each visit from baseline. RESULTS: 108 patients with 54 in each group were enrolled. During 1-year follow-up, the relapse rate was significantly higher in maintenance group than in intensive group, regardless of all enrolled patients or those in remission [24.1% (13/54) vs. 9.1% (5/54), p=0.039; 26.2% (11/42) vs. 5.3% (2/38), p=0.026, respectively]. Although GS and PD scores were decreased at 12 months in both groups, the decline was more remarkable in intensive group than in maintenance group. The improvement of clinical disease activity score was only observed in intensive group, not maintenance group. Adverse events were comparable between two groups. Abnormal liver function tests were observed in 24 (22%) patients with 16 from intensive group. CONCLUSION: Intensive therapy can alleviate subclinical synovitis on ultrasound and clinical disease activity, and prevent relapse in RA patients who have achieved clinical remission or low disease activity, with comparable safety profiles to maintenance therapy. REGISTRATION NUMBER: ChiCTR2000029279.
引用
- Zhao J, Wang Y, Geng Y, et al. Intensive therapy alleviates subclinical synovitis on ultrasound and disease activity and reduces flare in rheumatoid arthritis patients who have achieved clinical target - a randomized controlled trial. Semin Arthritis Rheum. 2020. PMID: 32512262. doi:10.1016/j.semarthrit.2020.05.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。